3 March
2025
Oxford BioDynamics
Plc
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share
Options
Oxford BioDynamics Plc (AIM: OBD,
the Company), a precision clinical diagnostics company
bringing specific and sensitive tests to the practice of medicine
based on its EpiSwitch® 3D genomics platform, announces that it has today granted a total of
218,000,000 options over its ordinary shares of 0.1 pence each
("Ordinary Shares"), to Group employees and advisers, including
certain directors and PDMRs of the Company, as outlined in the
table below.
The options were granted under the
Company's 2016 Employee and Non-Employee Share Option Plans
with an exercise price of 0.55p
per share, being the closing share price on 28
February 2025, the business day immediately preceding the grant of
the options. Prior to the grant, Chief Financial Officer Paul
Stockdale surrendered 70,000 share options originally awarded in
2018.
96,000,000 options have been award
to Executive Chairman Iain Ross; 4,000,000 of these options will
vest immediately and the remaining 92,000,000 options will vest in
23 equal instalments on the final day of each month to January
2027. All other newly-granted options will vest in three equal
tranches on the first, second and third anniversaries of the date
of grant. Vested options will remain exercisable up to and
including the tenth anniversary of the date of grant.
Following this grant, the
individuals referred to above hold options over Ordinary Shares and
are interested in Ordinary Shares as follows:
|
|
New
options granted
|
Total
number of options over Ordinary Shares
|
Ordinary
Shares held
|
|
Number
|
% of
current issued share capital
|
|
Iain Ross, Executive Chairman
|
96,000,000
|
96,000,000
|
10,000,000
|
0.51
|
|
Alexandre Akoulitchev, Chief Scientific Officer
|
18,000,000
|
19,596,131
|
7,562,296
|
0.39
|
|
David Blum, SVP of Marketing
|
18,000,000
|
18,462,500
|
744,611
|
0.04
|
|
Thomas Guiel, Chief Operations Officer
|
18,000,000
|
18,650,000
|
1,288,146
|
0.07
|
|
Ewan Hunter, Chief Data Officer
|
18,000,000
|
18,660,000
|
722,754
|
0.04
|
|
Paul Stockdale, Chief Financial Officer
|
18,000,000
|
18,980,000
|
3,077,919
|
0.16
|
The notifications below, made in
accordance with the requirements of UK Market Abuse Regulation,
provide further details:
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Alexandre Akoulitchev
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Director/PDMR
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of 0.1 pence each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Grant of share options
|
|
c)
|
Price(s) and volume(s)
|
18,000,000 ordinary shares at an exercise price
of 0.55 pence per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
David Blum
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of 0.1 pence each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Grant of share options
|
|
c)
|
Price(s) and volume(s)
|
18,000,000 ordinary shares at an exercise price
of 0.55 pence per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Thomas Guiel
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of 0.1 pence each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Grant of share options
|
|
c)
|
Price(s) and volume(s)
|
18,000,000 ordinary shares at an exercise price
of 0.55 pence per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Ewan Hunter
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of 0.1 pence each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Grant of share options
|
|
c)
|
Price(s) and volume(s)
|
18,000,000 ordinary shares at an exercise price
of 0.55 pence per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Iain Ross
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Director/PDMR
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of 0.1 pence each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Grant of share options
|
|
c)
|
Price(s) and volume(s)
|
96,000,000 ordinary shares at an exercise price
of 0.55 pence per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
3 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a)
|
Name
|
Paul Stockdale
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Director/PDMR
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford BioDynamics Plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of 0.1 pence each
ISIN:
GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Surrender and grant of share options
|
|
c)
|
Price(s) and volume(s)
|
Options over 70,000 ordinary shares at an
exercise price of £1.70 per share cancelled
Options over 18,000,000 ordinary shares at an
exercise price of 0.55 pence per share granted
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Dates of the transactions
|
28 February, 3 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
-Ends-
For further
details please contact:
|
Oxford
BioDynamics Plc
|
Tel: +44 (0)1865 518910
|
|
Iain Ross Executive Chairman
Paul Stockdale, CFO
|
|
|
Shore Capital
- Nominated Adviser and Broker
|
Tel: +44 (0)20 7408 4090
|
|
Advisory: Stephane Auton / Lucy
Bowden
Broking: Fiona Conroy
|
|
|
OAK Securities
- Joint Broker
|
Tel: +44 (0)20 3973 3678
|
|
Jerry Keen / Henry Clarke / Damion
Carruel
|
|
|
WG Partners -
Joint Broker
|
Tel: +44 (0)20 3705 9330
|
|
David Wilson / Claes Spång / Satheesh
Nadarajah / Erland Sternby
|
|
|
Camarco -
Financial PR
|
Tel: +44 (0)20 3757 4980
|
|
Marc Cohen / Tilly Butcher / Fergus
Young
|
OBDFinancial@camarco.co.uk
|
Notes to
Editors
About Oxford
BioDynamics Plc
Oxford BioDynamics
Plc (AIM: OBD) is an international biotechnology company, advancing
personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available
products: the EpiSwitch®
PSE (EpiSwitch Prostate Screening
test) and EpiSwitch®
CiRT (Checkpoint Inhibitor Response Test)
blood tests. PSE boosts the predictive accuracy of a PSA test from
55% to 94% when testing the presence or absence of prostate
cancer. CiRT is a highly accurate (85%) predictive response
test to immuno-oncology checkpoint inhibitor treatments.
The tests are based
on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and
monitoring of biomarkers to diagnose patients or determine how
individuals might respond to a disease or treatment.
OBD's clinical
smart tests have the potential to be used across a broader range of
indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal
health.
The Group's
headquarters and UK laboratories are in Oxford, UK.
Its US operations and clinical laboratory are in Maryland,
USA, along with a reference laboratory in
Penang, Malaysia.
OBD is listed on
the London Stock Exchange's AIM (LSE: OBD). For more information,
please visit the Company's website, www.oxfordbiodynamics.com,
X (@OxBioDynamics) or LinkedIn.
